A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Simple Search

You could also try: marks (231), results (1000)

Afatinib Ver 1

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Regimen AFATINIB NSCLC - Afatinib Indication Treatment of locally advanced or metastatic non-small
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/AfatinibVer1.pdf

Vinblastine Ver 1.1

Description
Chemotherapy Protocol LYMPHOMA VINBLASTINE Regimen Lymphoma – Vinblastine Indication Non-Hodgkin’s Lymphoma Hodg
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Vinblastine-Ver-1.1.pdf

Chlorambucil Ver 1.1

Description
Chemotherapy Protocol LYMPHOMA CHLORAMBUCIL There are multiple versions of this protocol in use. Please ensure you have the correct protocol for
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Chlorambucil-Ver-1.1.pdf

Isatuximab VRD weekly

Description
Chemotherapy Protocol Myeloma Isa-VRD weekly Isatuximab-Lenalidomide-Bortezomib-Dexamethasone (20) Regimen Myeloma – Isa-VRD weekly Isatuximab-Lenalidomide-Bortezomib-Dexamethasone (20
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Isatuximab-VRD-weekly-Ver1.pdf

2025 WDES report and action plan

Description
Workforce Disability Equality Standard Annual Report 2025 1 Executive Summary The Workforce Disability Equality Standard (WDES) is a set of ten metrics
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Equality-reports/2025-wdes-report-and-action-plan.pdf

Papers Trust Board - 13 May 2025

Description
Agenda Trust Board – Open Session Date Time Location Chair Apologies In attendance 13/05/2025 9:00 - 13:00 Conference Room
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2025-Trust-documents/Papers-Trust-Board-13-May-2025.pdf

Papers Trust Board - 27 July 2023

Description
Date Time Location Chair Agenda Trust Board – Open Session 27/07/2023 9:00 - 13:15 Conference Room, Heartbeat/Microsoft Teams
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2023-Trust-documents/Papers-Trust-Board-27-July-2023.pdf

Annual-report-2018-19

Description
ANNUAL REPORT AND ACCOUNTS 2018/19 incorporating the quality account 2018/19 Presented to Parliament pursuant to Schedule 7, paragraph 25
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/annual-report-2018-19.pdf

BV-CHP Brentuximab vedotin-cyclophosphamide-doxorubicin-prednisolone Ver1

Description
Chemotherapy Protocol LYMPHOMA BRENTUXIMAB VEDOTIN-CYCLOPHOSPHAMIDE-DOXORUBICIN-PREDNISOLONE (BV-CHP) Regimen • Lymphoma – Brentuximab vedotin-cyclophosphamide-doxorubicin-prednisolone Indication Brentuximab vedotin in
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/BV-CHP-Brentuximab-vedotin-cyclophosphamide-doxorubicin-prednisolone.pdf

Gilteritinib

Description
Chemotherapy Protocol Acute Myeloid Leukaemia GILTERITINIB Regimen  AML - Gilteritinib Indication Gilteritinib for treating relapsed/refractory FLT3 mutation positive myeloid leukaemia in
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/Gilteritinib.pdf
321 to 330 of 548
Previous … 31 32 33 34 35 … Next